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Resection is the gold standard in the treatment of liver metastases from colorectal 
cancer. An internal cooled radiofrequency electrode was described to achieve tissue 
coagulation to a greater margin width.  The aim of this study is to determinate if a RF-
assisted transection device (RFAT) has any effect on local hepatic recurrence (LHER) 
compared to conventional technologies.  
A study population of 103 patients who had undergone a hepatic surgical resection was 
retrospectively analysed. Patients were classified into two groups according to the 
device used: a RF-assisted device (RFAT group; n=45) and standard conventional 
devices (control group; n=58). LHER was defined as any growing or enhancing tumour 
in the margin of hepatic resection during follow-up. Cox proportional models were 
constructed and variables were eliminated only if p>0.20 to protect against residual 
confounding. To assess the stability of Cox’s regression model and its internal validity, 
a bootstrap investigation was also performed. 
Baseline and operative characteristics were similar in both groups. With a mean follow-
up of 28.5 months (range 2-106), in patients with positive margins, we demonstrated 
0% of LHER in RFAT vs. 27% in control group (p=0.032). In the multivariate analysis 
five factors demonstrated significant influence on the final model of LHER: RFAT 
group, size of the largest metastases, number of resected metastases, positive margin 
and usage of Pringle-manoeuvre.   
This study suggests that parenchymal transection using a RFAT able to create deep 
thermal lesions may reduce LHER especially in case of margin invasion during 
transection. 




Colorectal carcinoma (CRC) is one of the most common malignant tumours 
and accounts for at least one million new cases worldwide each year. Liver 
metastases occurs in 40-60% of CRC patients [1]. 
Liver resection has been accepted as ‘gold standard’ for treatment, resulting in 5-year 
survival rates of up to 58% [2]. However, after resections with curative intention, 
recurrences in the remaining liver are observed in up to 50% of patients and are among 
the most important determinants of survival [3, 4]. Traditionally, 1-cm margin was 
considered necessary to avoid liver recurrence and optimize long-term survival [4–14]. 
Ambiru et al.[3] described micrometastases located at a median of 3 mm from the 
metastatic tumour edge in 31% of their patients. Also, it has to be taken into account, 
that minimal margins are frequently linked with extensive disease and greater tumour 
burden[15–17]. These findings may account for a poorer liver disease outcome in 
patients with lower resection margin [16, 18, 19]. In any case, resection margin 
involvement (positive margin) is one of the leading independent predictors for hepatic 
recurrence [18, 19]. In this regard, few studies have evaluated the local hepatic 
recurrence -LHER- (or its surrogate variable, the local recurrence-free survival) in the 
resection margin after resection of the liver [20, 21], especially in relation to the positive 
margin of the liver resection.  
Radiofrequency assisted transection of the liver (RFAT) is a relatively new technique of 
liver resection that employs similar currents (in 300 -500 kHz range) and devices  than  
Radiofrequency ablation (RFA) of the liver but with different aim and approach [22, 
23]. Whereas RFA is based on delivering the current in the tumour itself by electrodes 
with the aim of ablating the tumour without its removal, and with similar or sometimes 
worse results than tumour resection [24, 25]. RFAT aims to remove the tumour in a 
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bloodless way by means of margin ablation of the remnant liver. Interestingly, some 
radiofrequency-assisted (RF-assisted) devices have been shown to improve resection 
margin during hepatectomy [26]. However, to our knowledge, no previous references 
have demonstrated any definitive effect on LHER. Previous studies of our group have 
shown that RF-assisted liver transection could achieve a wide ablation margin (up to 1 
cm) without increasing the risk of thermal damage in nearby structures [22, 27–30]. In 
this setting, the aim of this study was to determinate whether RF-assisted liver 
transection reduces local hepatic recurrence over the standard methods especially when 
this margin was positive.  
 
MATERIAL AND METHODS 
From September 2006 to July 2015, all patients who underwent partial 
hepatectomy at the Hospital del Mar (Barcelona, Spain) were considered to be included 
in this study. Patients were entered prospectively into a computer database. This 
database was created for this study and was filled during follow up of the patients and 
retrospectively analysed. The inclusion criteria were colorectal liver metastases to be 
removed by any type of liver resection, via open or laparoscopic surgery with no 
evidence of unresectable extrahepatic disease. The exclusion criteria were primary liver 
and cyst tumours, metastases of non-colorectal origin and those patients treated only by 
tumour ablation.  With these criteria, 103 patients were enrolled in the study and were 
allocated either to the control group (n=58) or radiofrequency-assisted transection group 




Figure 1. Flow chart of the study 
 
All patients signed an informed consent before surgery. All patients also underwent 
careful preoperative assessment of their disease, including spiral computed tomography 
or magnetic resonance imaging.  
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All the procedures were performed by the same surgeons (F.B., I.P. and L.G.). For open 
surgery, the procedure was similar to that described in Phase I-II studies [29, 30]. 
Alternatively, in the laparoscopy, after the pneumoperitoneum was established and the 
exposure obtained, laparoscopic ultrasound was used to identify the tumour. In both 
groups the dissection was carried out with standard devices such as CUSA (Cavitron, 
Stamford, CT, USA), stapler transection, bipolar forceps and Ligasure (Valleylab, 
Boulder, CO, USA). Hemostasia was obtained in the control group with a combination 
of stitches, bipolar forceps and Ligasure including even sutures or clips and in the 
RFAT group (RF-assisted transection) it was performed with Coolinside RF-assisted 
device (Apeiron Medical, Valencia. Spain) which has been described in detail elsewhere 
[22, 27–30]. The hemostasia in RFAT group was achieved by the above mentioned 
device by delivering RF power through an internally cooled electrode and creating 
larger coagulation zones (up to 1 cm) depending on the ablation time. The decision to 
use RFAT was based on preferences to get complete hemostasia and availability of the 
system but never based on neither tumoral stage, size or number of nodules.  
In patients subjected to laparoscopy approach in the RFAT group, it was introduced 
through a 12-mm trocar, and then the resection line was marked on the liver capsule 
using a conventional electrocautery or the RF device itself.  
After discharge, a follow-up appointment was made with all patients in the first month 
and then every 6 months. At each follow-up visit, in addition to a clinical examination 
and determination of the carcinoembryonic antigen level, computed tomography or 
magnetic resonance imaging was performed.  While all the clinical variables were 
considered as secondary outcomes, the primary outcomes of the study were overall 
survival, hepatic and local hepatic recurrence and positive margins.   
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The overall survival (OS) time was defined as the interval between the first liver 
operation and death or the last visit to the outpatient clinic through January 2016. 
Positive margin was defined as the presence of any exposed tumour along the line of 
transection or the presence of tumour cells at the line of transection detected by 
histological  examination according to Figueras et al. [18]. Similarly to Zorzi et al.[20], 
LHER was pragmatically defined when a later follow-up CT demonstrated any growing 
or enhancing tumour in the margin of hepatic resection specifically reviewed to this 
aim. On the other hand, hepatic recurrence (HER) was considered when any growing in 
the rest of the liver or/and in the margin of transection was detected. Furthermore, we 
evaluated the extrahepatic disease (EED) similarly to Evrard et al.[21], which was 
defined as the presence of cancer disease outside the liver at any time of the study.     
Other definitions of variables employed in this study were: 
- Resection margin: minimum distance from the edge of the nearest metastases to the 
transection line measured in millimetres, according to Pawlik et al.[16] 
-  Number of metastases: number of metastases assessed by appropriate 
histopathological study in the liver specimen. 
- Liver failure: an increased international normalized ratio and concomitant 
hyperbilirubinemia (according to the normal limits of the local laboratory) on or 
after postoperative day 5, according to Rahbari et al. [31] 
 
Statistical analysis   
  Patient’s demographics, primary and liver tumour characteristics, surgical 
therapy, history of chemotherapy and follow-up information were entered prospectively 
into the computer database. Patients were distributed in two groups: RFAT group and 
control group. The chi-square test was used to compare frequencies, whereas mean 
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values of variables were compared using the Student t-test between both groups.  
Concerning the overall survival (OS), HER and LHER, we performed both a global 
statistical analysis and a stratified analysis according to a positive or non-positive 
resection margins. Given that, the main goal was to construct a model that explained 
causality on OS, HER and LHER, predictors necessary to face validity, as well as those 
that behave like confounders were included in the model [32].  
Thus, following Maldonado and Greenland [33], the potential confounders in both 
univariate and multivariate analyses (using Kaplan-Meier or Cox proportional models) 
were eliminated only if p>0.20, in order to protect against residual confounding. These 
low cut-points to include variables in the model are especially advisable in order to 
adjust for covariates in therapeutic studies to appropriately select even weak factors for 
the next step of the analysis [34]. For the rest of the remaining analyses, differences in 
variables were considered to be significant at a threshold of p<0.05. To assess the 
stability of Cox’s regression model and its internal validity a bootstrap investigation 
was performed similarly to Nordlinger et al.[11], and based on the method described by 
Altman [35]. The bootstrap method was based on the observation samples drawn from 
original population. Bootstrapping is a method for deriving robust estimates of 
confidence intervals for estimates such as the regression coefficients. In our study, ten 
thousand of the same sample size was obtained by randomly drawing records with 
replacement from the data set.  
Results were expressed as regression coefficients (β) with their corresponding bootstrap 
estimates (bias, bias-corrected accelerated (or BCa) percentile intervals and 
significance). In that regard these confidence intervals may be wider than the 
conventional ones but are credited to be more robust an accurate than them because 
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fewer assumptions about normality are required.  Statistical analyses were carried out 
with statistical software SPSS (Chicago, IL, USA). 
 
RESULTS 
Patient’s and liver resection characteristics 
During the study period, 438 patients were assessed for eligibility for this study 
(see Figure 1). One hundred and three patients suffering from colorectal liver metastases 
underwent hepatic resection and were allocated in the control group (n=58) or the 
RFAT group (n=45). During the analysis there were one withdrawal in the RFAT group 
because of period of survival being less than two month, and two in the control group 
because of period of survival being less than two month and unavailable local 
recurrence data, respectively. 
Table 1 summarizes the baseline and operative characteristics.  According to the 
significance threshold previously described, no differences were found in variables 
among groups. 
As shown in Table 2, no differences were observed in the rate of complications between 





Table 1. Baseline characteristics of patients involved in the study. 









30 (66.7) 0.676 
Age (years) a 67.1 ± 9.5 66.5 ± 11.1 0.765 
Primary rectum 15 (25.9) 13 (28.9) 0.922 
CEA (ng/ml) b 57 ± 353 49 ± 109 0.888 
Dukes  
   A  
   B  










Positive colorectal nodes (pN) a 2.58  ± 6.1 2.11  ± 5.4 0.685 
Synchronic presentation 30 (51.7) 24 (53.3) 0.981 
Bilobar presentation 21 (36.2) 20 (44.4) 0.397 
Major hepatectomy c 24 (41.4) 17 (37.8) 0.711 
Number of metastases a 2.07 ± 2 2.09 ± 1.7 0.876 
Size of the biggest metastases a 3.21 ± 2 3.81 ± 3.1 0.269 
Morbidity 25 (43.1) 15 (33.3) 0.313 
Mortality 2 (3.4) 2 (4.4) 0.795 
Adjuvant chemotherapy after colorectal 
surgery 31 (53.4) 21 (46.7) 0.495 
Neo-adjuvant chemotherapy before hepatic 
surgery 18 (31) 17 (37.8) 0.474 
Adjuvant chemotherapy after surgery  39 (67.2) 22 (50) 0.079 
Positive margin 15 (26) 15 (33) 0.408 
Extrahepatic disease at hepatectomy 9 (15.6) 5 (11.1) 0.518 
Laparoscopic  approach  18 (31) 16 (36) 0.628 
Pringle  maneuver (min) 8.4 (17.1) 3.5 (8.4) 0.060 
Differences in variables were considered to be significant at a threshold of p<0.05 and those 
with a p value <0.02 were included in the univariate and multivariate analysis. 
Values in parentheses are percentages. aContinuous variables are expressed as mean ± standard 
deviation. bCEA, carcinoembryogenic antigen expressed as mean ± standard deviation. cAt least 





Table 2. Mortality and morbidity in patients included in the study.  
Complications Control group (n=58) 
RFAT group 
(n=45) Total      p 
Mortality 2 (3%) 2 (4%) 4 (4%)  0.795 
 Abscess 2 (3%) 2 (4%) 4 (2%)  0.243 
 Biliary leak 4 (7%) 7 (16%) 11 (11%)  0.158 
 Hemoperitoneum 1 (2%) 1 (2%) 2 (2%)  0.856 
 Liver failure 8 (14%) 4 (9%) 12 (12%)  0.442 
 Wound infection 4 (7%) 5 (11%) 9 (9%)  0.452 
  Pneumonia 0 (0%) 1 (2%) 1 (1%)  0.254 
  Other complications 11 (19%) 9 (20%) 20 (19%)  0.895 
  Blood transfusion 12 (21%) 5 (11%) 17 (17%)  0.194 
Differences were considered to be significant at a threshold of p<0.05. 
 
Univariate analysis of prognostic factors on OS, HER and LHER  
With a mean follow-up of 28.5 months (range 2-106), the 1, 3 and 5-year global 
OS was 93%, 62% and 42%, respectively. The global cumulative HER were 20%, 43% 
and 49% and LHER were and 5%, 11% and 11% for 1, 3 and 5-year, respectively. In 
this last set of results, six patients presented LHER in the control group (according to 
the above definition) and just one, in the RFAT group (see Figure 2). Concerning the 
management of the local recurrence, just one of them was intended for hepatic 
resection, but during the exploration peritoneal dissemination was also found (in 
addition to histologically proven recurrence at the site of the previous hepatic resection). 
In the remaining patients, no surgical option was possible due to the progression of the 
illness. However, five patients were subjected to adjuvant chemotherapy (4 in control 





Figure 2. (A) Local hepatic recurrence in all patients (LHER) (B) and LHER in cases with 
positive margin stratified by treatment group using Kaplan-Meier method with a mean follow-
up of 28.5 months. The log-rank test demonstrated a significance of 0.177 and 0.058, 
respectively.  
 
Six variables demonstrated influence on OS taking into account the significance 
threshold previously described: RFAT group, size of the biggest metastases, morbidity, 
adjuvant chemotherapy, extrahepatic disease and Pringle manoeuvre usage during 
hepatectomy (Table 3).  Similarly on HER, the following variables showed significant 
influence: RFAT group, size of the biggest metastases, node-positive of the primary 
tumour, number of metastases, bilobar presentation, morbidity, neo-adjuvant 
chemotherapy, extrahepatic disease and Pringle manoeuvre usage during hepatectomy. 
However, only six variables showed significant influence on the LHER analysis: RFAT 
group, size of the biggest metastases, number of metastases, positive margin, 
extrahepatic disease and Pringle manoeuvre usage during hepatectomy.   
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Table 3.  Univariate and multivariate analysis of prognostic factors on OS, HER and LHER.  
Variable 
OS HER LHER 




















RFAT group -0.9 -0.05 -1.7, -0.2 0.04 -0.8 -0.06 -1.8, 0.001 0.06 -1.6 -4.0 -19.8, 1.5 0.1 
Size of the biggest 
metastases 0.07 -0.002 -0.03, 0.2 0.04 0.1 -0.009 -0.04, 0.2 0.01 0.2 0.3 -3.2, 9.2 0.01 
Number of node-
positive primary      0.04 -0.002 -0.03, 0.09 0.02     
Number of metastases     *  * * 0.1 -1.5 -7.1, 0.3 0.2 
Bilobar presentation     *  * *     
Morbidity 0.6 0.06 -0.2, 1.7 0.1 *  * *     
Neo-adjuvant 
chemotherapy     0.6 0.03 -0.2, 1.5 0.09     
Adjuvant 
chemotherapy -1.5 -0.06 -0.06, -0.8 <0.01         
Positive margin         2.0 3.5 -11.4, 99.9 0.04 
Extrahepatic disease 0.9 0.05 0.04, 2.0 0.02 1.9 0.1 0.9, 3.6 <0.01 *  * * 
Pringle  manoeuvre *  * * *  * * 0.05 0.03 -1.7, 1.2 0.001 
In order to protect against residual confounding, data are eliminated only if p>0.2. Provided data are adjusted variables in the final multivariate model.  
*Variables above this significance threshold in univariate analysis which did not remain significant in the multivariate analysis. #Bootstrap estimates are based 
on 10000 samples. 
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Multivariate analysis of prognostic factors on OS, HER and LHER 
Five variables on each survival variable demonstrated significant influence in 
the final model taking into account the same significance threshold. Two of them were 
present on OS, HER and LHER: RFAT group and size of the biggest metastases (see 
Table 3). Interestingly, on LHER three additional variables remained in the final model: 
number of metastases, positive margin and Pringle manoeuvre use. Specifically on 
LHER, all factors increased the risk of local hepatic recurrence except RFAT group 
which seemed to reduce the associated risk (β= ̵ 1.6). 
 
LHER in positive resection margins 
When we selected patients with positive margins, 4 patients out of 15 presented 
LHER in the control group (27%), while no patients out of 15 presented LHER in the 
RFAT group (0%). These differences were statistically significant in this univariate 
analysis (p=0.032, chi-square test). This difference among groups nearly reached 
significance in the Kaplan-Meier method (p=0.058) (Figure 2-B). On the contrary, as 
expected, LHER in patients with negative resection margins was similar between 
control and RFAT group (p=0.98 in chi-square test and p=0.765 in Kaplan-Meier test). 
 
DISCUSSION 
     The resection margin of colorectal metastasis is currently the most important factor 
that is under the surgeon’s control[7, 12] with a significant impact on hepatic recurrence 
and a determinant of survival [4, 14, 16, 19, 36–38]. Recent publications have 
advocated that a subcentimeter resection margin should not preclude colorectal 
metastases resection since a non-positive margin can be obtained [18]. The incidence of 
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LHER ranges from 7 to 17% [20, 21] or even higher when non-anatomical resections 
were performed and it is usually linked with positive margin during hepatectomy in a 
risk-ratio of over 10% [20]. In spite of its relevancy, this variable is rarely reported 
because requires careful and time-consuming evaluation of the margin status over time 
with appropriate image-study of each patient. In our study, with a mean follow-up of 
28.5 months we demonstrated 0% LHER in the RFAT group when a positive margin 
was observed during hepatectomy in comparison to 27% in the control (p=0.032 and 
Figure 2-B). This low risk of LHER in patients with positive margins in the RFAT 
group can be explained by a wide resection margin (up to 1 cm)  due to the ablation 
effect of RF-assisted device employed in this study as it was demonstrated in preclinical 
studies (also see Figure 3) [22, 27, 28]. As expected this positive effect was not 





Figure 3. (A) Photograph showing the remnant liver after removing the specimen (RFAT 
group, central hepatectomy). Notice the coagulated tissue in the remnant liver (two headed 
arrow) and the resection margin (asterisk). (B) The liver specimen of the same patient showing 
the margin of resection and the thickness of coagulated tissue (two headed arrow) which is in 
contact with the metastasis (arrows). The asterisk shows the correct position of the specimen. 
(C) Histological section of the resection margin of the specimen (see asterisk for correct 
position). Resection margin is marked with green ink. See tumor (“T”) and coagulated 
parenchyma (“P”) in contact with the margin. Notice that coagulated tumor did not impair 
correct evaluation of margin invasion. (D) CT of the same patient after 56 months of this liver 
resection, where no signs of local hepatic recurrence is observed. See the remaining ablated 




The benefit of the ablation effect on the resection margin may be weaker or diluted 
when all of the patients are taken into account (with positive and non-positive margin) 
but, in fact, the global analysis with an appropriate selection of confounding factors 
found some effect on all conventional survival analysis (OS, HER and LHER) which 
were confirmed by bootstrapping resampling methods in all cases. Bootstrapping is very 
useful to assess internal validity when the assumptions of parametric methods are in 
doubt (as in the case of regression models with heteroscedastic residuals fit to small 
samples or not normal distributions). In our regression model the bias of the estimates 
and their variability were measured with this robust statistical method which confirmed 
the influence of the referred variables.    
     Several limitations of this study should be also addressed: 
- Accurate assessment of the resection margin in hepatic surgery can be difficult. 
Therefore, the lack of more direct metastases measurements is related to CT or 
MR sensitivity. 
- Even though this is a controlled study of an homogeneous cohort of patients, it is 
not a randomized study. That is why a high control for confounding factors has 
been applied in univariate and multivariate analysis.  
     In conclusion, our findings provides evidence supporting the concept that 
radiofrequency assisted transection of the liver associated with a deep thermal lesions 
may reduce local hepatic recurrence, especially in case of margin invasion during 
transection. However, in spite of this positive effect on local hepatic recurrence, 
surgeons should continue to endorse the conventional guidelines of negative margin 
preservation. In any case, this technique could be especially advantageous when R0 
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